



Collaborative Working Executive Summary

Project title	Improving Medical Retina Services by Increasing Diagnosis and Treatment Capacity at Calderdale and Huddersfield NHS Foundation Trust (CHFT) Joint Working Project.
Project partners	Calderdale and Huddersfield NHS Foundation Trust Bayer plc
Project summary	<p>Calderdale and Huddersfield NHS Foundation Trust and Bayer plc are working in partnership under a joint working agreement to redesign and re-purpose a newly identified space within Acre Mills Out-patients to set up an additional diagnostic suite and macular treatment theatre for medical retina patients.</p> <p>The diagnostic suite and macular treatment theatre will provide the opportunity to reconfigure the medical retina service to improve capacity and efficiency and ensure timely reviews in line with the earliest appropriate clinical date (EACD).</p> <p>The project also intends to design and implement patient pathways that aim to change how medical retina services are delivered, in line with NICE guidelines.</p> <p>These proposed changes will see the recruitment, training and deployment of entry level technicians and appropriate clinical staff, alongside the purchase and implementation of the required imaging equipment. The financial contribution from Bayer will not be utilised for workforce or training purposes.</p>
Expected benefits to patients/patient care/NHS and Bayer	<p>Expected benefits for patients are:</p> <ul style="list-style-type: none"> • Aims to improve timely access to medical retina services by increasing available appointments per week from current baseline. • Aims to reduce waiting time for diagnostic assessment appointments compared to baseline, to meet hospital performance targets set for both new and follow-up patients. • Aims to reduce time from referral to treatment and diagnosis to treatment versus baseline measurements. • Aims to improve the patient experience whilst in the ophthalmology department. To be measured using a bespoke questionnaire. <p>Expected benefits for the Trust are:</p> <ul style="list-style-type: none"> • Aims to continue providing full compliance with NICE and national targets for both age-related macular degeneration and diabetic retinopathy , by designing treatment pathways based regional treatment pathways, current NICE and national guidelines. • Aims to reduce current waiting times in clinic compared to baseline. • Intends to identify and treat all patients referred into the medical retina service more timely and in line with earliest appropriate clinical date compared to baseline, through increased capacity.

	<p>Expected benefits for Bayer are:</p> <ul style="list-style-type: none">• Demonstrating our commitment to ophthalmology patient care by collaborating on a large strategic project.• Opportunity to share learnings and best practice from this collaboration within the ophthalmology community having received permission from the trust to do so.• Increasing injection and diagnostic capacity and efficiency. For transparency, Bayer has a NICE approved treatment in this therapy area that CHFT is already using in line with established NICE and Royal College guidance, and the evidence-based literature. Any change to the proportion of patients receiving Bayer’s NICE approved treatment will only be based on the latest published guidance and evidence, and not in response to Bayer’s financial contribution to this project.
Start date	May 2022

Published on www.bayer.co.uk

RP-PF-OPHT-GB-0592 | May 2022